Information about adverse effects from patients, reported by health professionals or patients themselves, makes the long journey, via the national pharmacovigilance centre, into WHO’s global database, where medicines safety issues across the world can be identified.
Countries participating in the WHO Programme forward their reports to UMC where they are entered into VigiBase, the WHO global database of individual case safety reports, which is maintained by UMC. VigiBase contains reports collected over nearly half a century. All reports are anonymous.
Data is just the first step towards understanding patients' experiences.Making sense of the data
More than 150 countries that have national pharmacovigilance centres are members or associate members of the WHO Programme for International Drug Monitoring. UMC has provided technical and scientific support for this expanding programme since 1978.
This is the foundation of much of UMC’s research and the source for its various unique and important professional reference works, such as the WHODrug portfolio.
Read more about VigiBase, the WHO global database
is a user-friendly interface available for public use. VigiAccess opens the door to VigiBase and provides the opportunity to explore high-level statistical data on suspected adverse effects reported to the WHO Programme.
Follow the soulful rhythms of the Take&Tell campaign to gain information about why it’s important to report adverse effects. The campaign also provides you with an app to help note and discuss your medicines safety issues with your health professional.